Comment on "Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study".

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Annals of hepatology Pub Date : 2025-09-24 DOI:10.1016/j.aohep.2025.102127

Qing Chen, Meng Meng, Chunhui Yuan

引用次数: 0

查看原文本刊更多论文

评论“Camrelizumab联合经导管动脉化疗栓塞和索拉非尼或lenvatinib治疗不可切除的肝细胞癌：一项多中心回顾性研究”。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of hepatology 医学-胃肠肝病学

CiteScore

7.90

自引率

2.60%

发文量

183

审稿时长

4-8 weeks

期刊介绍： Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.